SNIPR Biome receives funding from CARB-X to support advancement of CRISPR medicine SNIPR001 into clinical trials in haematological cancer patients April 23, 2024
Arvinas and Novartis to Develop and Commercialize PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer April 16, 2024
Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated April 16, 2024
OSE Immunotherapeutics Receives €8.4 M in Public Funding for Registrational Ph 3 Trial of Cancer Vaccine Tedopi® in Lung Cancer April 16, 2024
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6 April 16, 2024
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer April 16, 2024
Novartis implements manufacturing adjustments for ribociclib to ensure alignment with latest regulatory standards in eBC by end of Q2 April 16, 2024
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors April 9, 2024
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas April 9, 2024
Gilead And Xilio Announce Exclusive License Agreement For Tumor-Activated IL-12 Program April 2, 2024
Edgewood Oncology raises $20 Million in Series A Financing to Advance BTX-A51 in Patients with Hematologic Malignancies and Genetically-Defined Solid Tumors April 2, 2024
Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma March 26, 2024
AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer March 26, 2024
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas March 26, 2024
Clasp Therapeutics Launches with $150 Million to Pioneer Precision IO Using Next-Gen T Cell Engagers with Unparalleled Specificity March 26, 2024
Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline March 18, 2024
IDEAYA to Evaluate IDE161 in Combination with KEYTRUDA in Patients with Endometrial Cancer March 18, 2024
Domain Therapeutics and Chime Biologics announce manufacturing agreement to advance novel anti-CCR8 antibody for cancer immunotherapy March 18, 2024
Asgard Therapeutics announces €30 million Series A financing to advance its first-in-class in vivo cell reprogramming platform for immuno-oncology March 18, 2024
